**Circular RNAs and Their Role in Pediatric Disease Pathogenesis**

Abstract

Circular RNA (circRNA) and long non-coding RNA (lncRNA) play a crucial role in gene regulation through microRNA (miRNA) pathways. Initially viewed as a molecular curiosity or a byproduct of RNA splicing processes, circRNAs were largely overlooked. Their biological relevance and diversity were only realised with the advent of high-throughput sequencing technologies in the 2010s. In this review manuscript, the role of circular RNA will be further evaluated in pediatric disease pathogenesis. Recent studies emphasise the importance of circRNA and lncRNA in competing endogenous RNA (ceRNA) networks in pediatric cancer. Circular RNA (circRNA) is a single-stranded RNA molecule that forms a closed loop structure, lacking 3' and 5' ends found in linear RNA. CircRNA has unique properties, including resistance to degradation and stability in cells. Some circRNAs are derived from protein-coding genes and have been shown to regulate gene expression. They have also been associated with diseases like cancer. In eukaryotes, genes are split by non-coding introns, and during RNA splicing, introns are removed, leaving only exons in the mature mRNA. Alternative splicing allows for different protein products from one RNA transcript. Exon scrambling, a non-canonical splicing event, can lead to different exon arrangements, impacting gene expression. Alu elements in flanking introns influence circRNA formation, and RNA editing can affect circRNA synthesis. CircRNAs can act as miRNA sponges, regulating gene expression. Genome-wide studies have identified circRNAs in various species, and their functions are still being explored. In recent years, circular RNAs (circRNAs) have emerged as key players in regulating cellular processes. Studies have identified specific circRNAs associated with NB progression. For instance, circAGO2 and circ-CUX1 have been linked to promoting growth and invasion of cancer cells by interacting with specific proteins. Moreover, Circ0093740 was identified as upregulated in WT samples, promoting proliferation and migration by sponging miR-136/145 and upregulating DNMT3A. Researchers found that SMN circ4-2b-3, detected in patient-derived serum exosomes, was associated with a strong response to Nusinersen in a subset of patients (Guerra et al. 2024). This suggests that SMN circ4-2b-3 could be a useful biomarker for predicting treatment response in type I SMA patients. Targeting circRNAs can be achieved using antisense oligonucleotides and silencing RNAs, with nanotechnology offering innovative delivery methods. CircRNAs are more stable than linear RNAs and have longer half-lives. They are predominantly found in the cytoplasm and may play roles in gene regulation and disease. Evolutionarily conserved circRNA mechanisms suggest their functional significance across species. CDR1as/CiRS-7 is an example of a circRNA that acts as a miRNA sponge, regulating gene expression. Wilms' tumour (WT) accounts for 6% of childhood tumours and 95% of pediatric kidney tumours. CircSLC7A6 was found to be upregulated in WT tumour samples, increasing cell apoptosis and repressing migration and invasion by targeting miR-107 and upregulating ABL2 expression. It was concluded that CircRNAs, stable and specific molecules involved in physiological processes and implicated in cancer, offer potential as clinical biomarkers and therapeutic targets in pediatric oncology.

**Keywords:** *Circular RNAs, non-coding RNA, pediatric disease, pathogenesis, Wilms Tumour, Spinal Muscle Atrophy*

Introduction

Circular RNA (circRNA) is a class of RNA molecules characterised by their circular structure. In contrast to linear forms of RNA, such as messenger RNA (mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA), circRNAs form a closed, continuous loop. This structure gives them increased stability compared to linear RNA molecules. circRNAs were originally discovered in the 1970s, but it was not until the 2010s that their functions and significance in biological processes began to be fully recognised. Initially viewed as a molecular curiosity or a byproduct of RNA splicing processes, circRNAs were largely overlooked. Their biological relevance and diversity were only realised with the advent of high-throughput sequencing technologies in the 2010s. These technological advances allowed researchers to more closely examine the complexity of the transcriptome (the total set of RNA molecules in a cell) and demonstrate the presence and diversity of circRNAs in many organisms (Bessiere et al. 2025). circRNAs perform a variety of functions in the cell that are still the subject of intensive research. Many circRNAs can serve as molecular "sponges" for microRNAs (miRNAs). By binding specific miRNAs, they can reduce the ability of these miRNAs to regulate their target mRNAs, leading to increased expression of the target genes (Nielsen et al., 2022). Some circRNAs can be transported to the cell nucleus, where they influence the transcription of certain genes, either by interacting with RNA polymerase II or other transcriptional regulators. circRNAs can also serve as binding partners for proteins, influencing their activity or localisation in the cell. Although it was long believed that circRNAs are non-coding, recent studies have shown that some circRNAs are capable of encoding proteins by utilising internal ribosome entry sites (IRES) (Miao et al., 2021). Again, Exosomal circRNAs offer several advantages, such as high stability, abundance, and long half-life. In addition to their aberrant expression in tumour tissues, exosomal circRNAs have been widely shown to be associated with the progression and clinical features of various cancers. They can serve as early diagnostic and prognostic markers for cancer (Zhang et al., 2023).

CircRNAs play a role in various physiological processes and are dysregulated in numerous diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases (Mo, 2023). Their stability and conserved expression in body fluids make them potential biomarkers for disease diagnosis and monitoring. CircRNAs are multifunctional molecules that have been shown to regulate gene expression transcriptionally and post-transcriptionally and exhibit distinct tissue- and development-specific expression patterns associated with a variety of normal and disease conditions, including cancer pathogenesis. Over the past years, due to their intrinsic stability and resistance to ribonucleases, particular attention has been drawn to their use as reliable diagnostic and prognostic biomarkers in cancer diagnosis, treatment, and prevention (Pisignano et al., 2023). Research on circRNAs is a rapidly growing field. Scientists are working to better understand the exact molecular mechanisms through which circRNAs exert their functions and further explore their potential use in biotechnology and medicine. Despite significant progress in recent years, much remains to be elucidated about the biological roles and the mechanisms of gene regulation by circRNAs. This review aims to evaluate the role of circular RNA in pediatric disease pathogenesis.

*Circular RNA and pediatric cancer*

With the advancements in high-throughput sequencing techniques, extensive studies are being conducted to understand the role of circRNAs in various diseases. Particularly, the relationship between circRNA and tumors cannot be ignored. Several studies have shown that circRNAs play a vital role in tumor occurrence, proliferation, metastasis, invasion, EMT, apoptosis, and cell cycle (Yu et al., 2021). CircRNAs play various roles in cellular functions, acting as miRNA and protein sponges, modulating transcription, and splicing (Galardi et al. 2022, Ahmadov et al. 2021, Latowska et al. 2020, Skrypek et al. 2020). Their aberrant expression in diseases suggests their potential as diagnostic and prognostic biomarkers due to their resistance to RNases. In cancer, circRNAs regulate tumour proliferation and invasion, making them promising therapeutic targets (De Tomi et al. 2024). Recent findings on circRNAs in pediatric solid cancers, including brain tumours, neuroblastomas, sarcomas, Wilms tumours, hepatoblastomas, retinoblastomas and gastric cancer were described (Wang et al. 2025, Lin et al. 2025, Li et al. 2025).

*Circular RNA and Medulloblastoma*

Medulloblastoma is a common malignant tumor in children affecting the central nervous system (Beylerli et al. 2025, Spinello et al. 2025, Nejadi Orang et al. 2024, Martinez de Estibariz et al. 2023, Liu et al. 2022, Rickert et al. 2021, Zhao et al. 2021). Despite advancements in traditional treatments like surgery, radiotherapy, and chemotherapy, some MB patients have a poor prognosis. Research is focusing on molecular targeted therapies to improve outcomes and reduce side effects. CircRNAs have emerged as potential targets in MB. Lv et al. identified circ-SKA3 and circ-DTL as differentially expressed circRNAs in MB compared to normal cerebellum tissues. Silencing these circRNAs suppressed cell proliferation, migration, and invasion in MB cell lines (Azatyan et al. 2022). Recent research found that circSKA3 promotes MB progression by sponging miR-383-5p, leading to FOXM1 regulation. Another study showed that circ-SKA3 decoys miR-326 to increase ID3 expression, promoting cell growth and invasion (Martinez de Estibariz et al., 2023). CircSKA3 was also linked to the miR-520 h/CDK6 axis in MB progression. These findings suggest circRNAs like circSKA3 play a role in tumour development and could be potential therapeutic targets.

*Circular RNA and Neuroblastoma*

Neuroblastoma (NB) is a common childhood cancer originating from primitive neuronal crest cells of the sympathetic nervous system, typically found in the adrenal medulla or paraspinal ganglia (Du et al. 2023, Fuchs et al. 2023, Karami Fath et al. 2022, Chen et al. 2023). It can either progress rapidly or resolve spontaneously, especially in infants. About 25% of cases present as a solitary mass treatable with surgery, while 60% have disseminated disease involving bone, bone marrow, lymph nodes, and liver. Patients with metastasis have poor survival rates. Despite advancements in understanding NB at a genetic and molecular level, the prognosis for metastatic disease remains grim. Research is ongoing to uncover mechanisms driving NB progression and identify new treatment targets (Zhang et al., 2025).

In recent years, circular RNAs (circRNAs) have emerged as key players in regulating cellular processes. Studies have identified specific circRNAs associated with NB progression. For instance, circAGO2 and circ-CUX1 have been linked to promoting the growth and invasion of cancer cells by interacting with specific proteins. Other circRNAs like circDGKB and circCUX1 have been shown to influence glycolysis and aggressiveness in NB cells by modulating gene expression. Additionally, circRNAs targeting microRNAs, such as miR-16-5p and miR-388-3p, have been implicated in NB pathogenesis. Further research has revealed dysregulated circRNAs in NB cell lines, with some originating from amplified regions of the MYCN gene. These circRNAs are associated with key signalling pathways and processes like epithelial-to-mesenchymal transition. High-throughput sequencing studies have identified differentially expressed circRNAs in NB tumours, some of which target miR-21, a regulator of proliferation and apoptosis. Notably, circRNAs like circPDE5A and circ\_0132817 have been found to modulate NB progression by regulating microRNAs and downstream targets like NOL4L. Recent studies have highlighted circRNAs like circ0125803 and circ\_0135889 as potential regulators of NB progression through interactions with microRNAs and target genes. CircKIF2A has also been implicated in promoting NB cell aggressiveness by targeting PRPS1. These findings underscore the potential of circRNAs as biomarkers and therapeutic targets in NB, although further validation is needed. Ongoing research aims to elucidate the precise roles of circRNAs in NB pathogenesis and their therapeutic implications for individual patients.

*Circular RNA and Rhabdomyosarcoma*

Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in children and adolescents, accounting for up to 3–4% of childhood cancer cases and approximately 50% of all sarcomas. Among the main RMS subtypes, embryonal (ERMS) and alveolar sarcomas (ARMS) account for 60% and 20% of all RMS cases, respectively. ARMS is associated with specific genetic alterations and generally has a worse prognosis due to its low response to treatment. In 2019, Rossi et al. found that circ-ZNF609 is upregulated in RMS cell lines, particularly in ARMS, and acts as a positive regulator of cell proliferation pathways. Knockdown of circ-ZNF609 induces a block of the G1–S transition, specifically in ERMS cells, with a decrease in p-AKT protein levels in both ERMS and ARMS cell types. Moreover, circ-ZNF609 is overexpressed in RMS primary tissues. In 2021, the same research group identified high expression of circVAMP3 in ARMS cell lines and demonstrated its involvement in cell cycle progression through AKT-related pathways (Galardi et al., 2022). Downregulation of circVAMP3 leads to the upregulation of CDKN1A and WEE1, which regulate the CCNB1/CDK1 complex, controlling the G2/M checkpoint, and the downregulation of AKT and ERK1, resulting in cell accumulation in the G2 phase.

*Circular RNA and Osteosarcoma*

Osteosarcoma (OS) accounts for approximately 35% of primary malignant bone tumours, with its metastatic form having the lowest survival rate among all pediatric cancers (Liu et al. 2021, Zhang et al. 2023, Liu et al. 2024, Liu et al. 2023, Yang et al 2023, Ren et al. 2019). MNAT1 protein is upregulated in OS tissues compared to normal bone tissue. Among the four miRNAs aberrantly expressed in OS and predicted to target MNAT1, miRNA-26a-5p shows a negative correlation with MNAT1 expression (Liu et al. 2024, Chen et al. 2022). The circRNA has\_circ-0001146 promotes MNAT1 expression by sponging miR-26a-5p, leading to increased proliferation and invasion ability.

*Circular RNA and Wilms Tumour*

Wilms' tumour (WT) accounts for 6% of childhood tumours and 95% of pediatric kidney tumours (Shu et al. 2025, Tian et al. 2022). Circ0093740 was identified as upregulated in WT samples, promoting proliferation and migration by sponging miR-136/145 and upregulating DNMT3A. Conversely, has\_circ\_0008285 (circCDYL) was downregulated in WT tissues, suppressing proliferation, migration, and invasion by upregulating TPJI expression. CircSLC7A6 was found to be upregulated in WT tumour samples, increasing cell apoptosis and repressing migration and invasion by targeting miR-107 and upregulating ABL2 expression.

*Circular RNA and Hepatoblastoma*

Hepatoblastoma (HB) is a significant liver cancer in infants, representing about 1% of all pediatric cancers (Li et al. 2025). Current treatment methods for HB include surgical resection, adjuvant chemotherapy, and liver transplantation. However, a high percentage of patients face a risk of relapse or metastasis, with a mortality rate exceeding 35% in advanced cases. In the study of HB, researchers have identified several circRNAs with potential roles in the disease. For example, circRNA has\_circ\_0015756 was found to be significantly upregulated in HB tissues and metastatic cell lines, and its silencing led to reduced cell viability, proliferation, and invasion. Predictive analyses suggested several miRNAs as potential targets of circ\_0015756, with functional experiments confirming the regulation of circ\_0015756 by miR-1250-3p (Wang et al., 2024). Other studies have highlighted the dysregulation of circRNAs in HB, such as has\_circ\_0000594 and circHMGCS1, which play roles in regulating tumour suppressor miRNAs and oncogenic pathways. Additionally, circ-STAT3 was identified as a promoter of HB tumour growth through its interaction with miR-29a/b/c-3p. Recent research has also explored the involvement of circRNAs in maintaining stemness in HB cells. CircRNA CDR1 and circSETD3 were found to influence stem cell populations and tumour progression in HB through interactions with miRNAs and downstream signalling pathways.

Overall, these studies shed light on the potential roles of circRNAs in HB pathogenesis and provide insights into novel therapeutic targets for this aggressive pediatric cancer (Li et al. 2022, Zhou et al. 2022).

*Circular RNA and Retinoblastoma*

Abnormal circRNA expression is closely linked to various ocular disorders, including retinoblastoma (RB), the most common eye cancer in children. Treatment approaches for RB have improved survival rates, but challenges remain in managing resistant disease. Understanding the molecular events in RB progression is crucial. Studies have shown that circRNAs like has\_circ\_0001649 play a role in RB development by regulating AKT/mTOR signalling. Other circRNAs, such as TET1-has\_circ\_0093996 and circTET1, impact RB progression by modulating gene expression and signalling pathways. Circ\_0075804 and circ\_ODC1 also influence RB cell proliferation through interactions with specific proteins and microRNAs. Additionally, circ\_0000527, circ\_0000034, circMKLN1, and circ-FAM158A have been implicated in promoting RB aggressiveness by regulating gene expression and cell growth (Asadi et al., 2022). Recent research has identified circ\_0084811 as a potential regulator of RB cell proliferation and apoptosis by targeting E2F5 through miRNA sponging. Understanding the role of circRNAs in RB pathogenesis could lead to novel therapeutic strategies for this cancer.

*Circular RNA and Blood Cancer*

This work is focused on the latest scientific evidence regarding circRNAs in solid pediatric tumours, but their role in blood cancers is also significant (Dashti et al. 2025, Filomena et al. 2024, Sun et al. 2024, Li et al. 2021, Tretti-Parenzan et al. 2024, Liu et al. 2023). CircRNAs can serve as clinical biomarkers for blood cancers due to their stability and abundance in bone marrow and body fluids (Poncelet et al. 2025, Wilson et al. 2024, Gutierrez-Camino et al. 2024, Liu et al. 2022, Babin et al. 2021, Liu et al. 2021). Several circRNAs have been identified as diagnostic and prognostic biomarkers in blood malignancies like multiple myeloma (MM), acute lymphocytic leukaemia (ALL), and juvenile myelomonocytic leukaemia (JMML) (Poncelet et al. 2025, Fu et al. 2023, Ye et al. 2023). For example, circRNAs involved in cell proliferation and tumor progression (e.g., circ-SMARCA5, hsa\_circ\_0007841) and chemoresistance (e.g., circRNA\_101237) have been identified in MM. In ALL, circPVT1 was found to promote leukemogenesis, while circRNF220 was suggested as a prognostic biomarker in AML (Deng et al. 2023). CircMCTP, circLYN, and circAFF2 were upregulated in JMML, indicating their role in the disease. The search for circRNAs in blood cancers is still in its early stages but holds promise for identifying biomarkers.

*Circular RNA and Spinal Muscle Atrophy (SMA)*

Spinal muscular atrophy (SMA) is a neuromuscular disorder that affects α-motor neurons. Nusinersen, an antisense oligonucleotide, is used to treat SMA by correcting splicing defects in SMN2 (Wirth et al., 2021). Identifying biomarkers to predict treatment response in SMA patients is crucial. SMN circular RNAs (circRNAs) as potential biomarkers for SMA were found (Guerra M et al. 2024). In a recent study, conducted at Fondazione Policlinico A. Gemelli in collaboration with Catholic University of Sacred Heart, included 19 type I SMA patients treated with Nusinersen (Guerra et al. 2024). Researchers found that SMN circ4-2b-3, detected in patient-derived serum exosomes, was associated with a strong response to Nusinersen in a subset of patients (Guerra et al. 2024). This suggests that SMN circ4-2b-3 could be a useful biomarker for predicting treatment response in type I SMA patients, although further research in larger cohorts is needed to confirm these findings (Guerra et al. 2024).

*Nanoparticles and Circular RNA Delivery*

Anticancer therapy requires the development of new strategies, with circular RNAs (circRNAs) emerging as a promising molecular target (Raca et al. 2024). CircRNAs are stable single-stranded RNA molecules with joined 5' and 3' ends, playing a role in cancer progression (Wan et al., 2024). Targeting circRNAs can be achieved using antisense oligonucleotides and silencing RNAs, with nanotechnology offering innovative delivery methods. Research is focused on developing nanoparticles (NPs) with enhanced biocompatibility and targeting capabilities for circRNA therapy (25). These NPs have potential applications in imaging and gene therapy.

*Conclusion*

Recent advancements in high-throughput technologies like sequencing and omics have enabled the discovery of circRNAs, which are conserved endogenous RNAs with tissue-specific expression and diverse functions. Dysregulated circRNA expression has been observed in various cancers, indicating their potential as cancer biomarkers. While their exact roles in cancer development and progression are not fully understood, circRNAs show promise for clinical applications in cancer diagnosis, prognosis, and treatment. However, further research is needed to fully characterise circRNAs and their implications in cancer. It is unlikely that a single circRNA can serve as a universal cancer biomarker, so a panel of cancer-associated circRNAs may be more effective for predicting and monitoring cancer. This approach could be particularly valuable in pediatric cancer, where novel biomarkers are needed for accurate risk assessment. CircRNAs, stable and specific molecules involved in physiological processes and implicated in cancer, offer potential as clinical biomarkers and therapeutic targets in pediatric oncology. Moreover, they could play an important role in Hirschsprung disease, necrotising enterocolitis, asthma, bronchopulmonary dysplasia, ARDS and Kawasaki disease.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.)

and text-to-image

generators have been used during the writing or editing of this manuscript

CONSENT

As per international standards, parental written consent has been collected and preserved by the author.

ETHICAL APPROVAL

As per international standards or university standards written ethical approval has been collected and preserved by the

author.

References:

Lin Z, Zhong C, Shi M, Long Q, Jing L, Yu Y, Chou J, Chen M, Lan M, Long F. Circular RNA TFRC/SCD1 mRNA interaction regulates ferroptosis and metastasis in gastric cancer. Cell Death Dis. 2025 Jun 5;16(1):436. doi: 10.1038/s41419-025-07759-x. PMID: 40473597; PMCID: PMC12141735.

Li Q, Cheng Y, Yang C, Tian M, Wang X, Li D, Li X, Qu J, Zhou S, Zheng L, Tong Q. Targeting the Exonic Circular *OGT*RNA/O-GlcNAc Transferase/Forkhead Box C1 Axis Inhibits Asparagine- and Alanine-Mediated Ferroptosis Repression in Neuroblastoma Progression. Research (Wash D C). 2025 May 23;8:0703. doi: 10.34133/research.0703. PMID: 40416363; PMCID: PMC12099056.

Poncelet L, Richer C, Gutierrez-Camino A, Veres T, Sinnett D. Long Circulating RNAs Packaged in Extracellular Vesicles: Prospects for Improved Risk Assessment in Childhood B-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2025 Apr 22;26(9):3956. doi: 10.3390/ijms26093956. PMID: 40362196; PMCID: PMC12071302.

Li SY, Liu ST, Wang CY, Bai YZ, Yuan ZW, Tang XB. Comprehensive circRNA expression profile and hub genes screening during human liver development. Ann Med. 2025 Dec;57(1):2497111. doi: 10.1080/07853890.2025.2497111. Epub 2025 Apr 25. PMID: 40285372; PMCID: PMC12035923.

Beylerli O, Musaev E, Ilyasova T, Sufianov A. lncRNAs and circRNAs: Emerging Players in Pediatric Medulloblastoma Pathology. Curr Med Chem. 2025 Apr 15. doi: 10.2174/0109298673354413250325073924. Epub ahead of print. PMID: 40237052.

Boichenko V, Noakes VM, Reilly-O'Donnell B, Luciani GB, Emanueli C, Martelli F, Gorelik J. Circulating Non-Coding RNAs as Indicators of Fibrosis and Heart Failure Severity. Cells. 2025 Apr 7;14(7):553. doi: 10.3390/cells14070553. PMID: 40214506; PMCID: PMC11989213.

Spinello Z, Besharat ZM, Mainiero F, Rughetti A, Masuelli L, Ferretti E, Catanzaro G. MiR-326: Role and significance in brain cancers. Noncoding RNA Res. 2025 Feb 25;12:56-64. doi: 10.1016/j.ncrna.2025.02.006. PMID: 40115178; PMCID: PMC11925037.

Dashti NR, Fadavi D, Rezaei R, Rahgozar S, Moafi A. Circulating lncRNA HOTAIR is a biomarker for pediatric acute lymphoblastic leukemia and mediator of miR-326 exosomal export. Sci Rep. 2025 Feb 10;15(1):4901. doi: 10.1038/s41598-025-87857-0. PMID: 39929912; PMCID: PMC11811015.

Bessière C, Meggetto F, Gaspin C, Fuchs S. Identification of Circular RNA Variants by Oxford Nanopore Long-Read Sequencing. Methods Mol Biol. 2025;2880:49-68. doi: 10.1007/978-1-0716-4276-4\_3. PMID: 39900754.

Wang Y, Yu Y, Yu J, Wang C, Wang Y, Fu R, Zhang C. The Role of the Dysregulation of circRNAs Expression in Glioblastoma Multiforme. J Mol Neurosci. 2025 Jan 22;75(1):9. doi: 10.1007/s12031-024-02285-5. PMID: 39841303.

De Tomi E, Orlandi E, Belpinati F, Patuzzo C, Trabetti E, Gomez-Lira M, Malerba G. New Axes of Interaction in Circ\_0079593/miR-516b-5p Network in Melanoma Metastasis Cell Lines. Genes (Basel). 2024 Dec 21;15(12):1647. doi: 10.3390/genes15121647. PMID: 39766913; PMCID: PMC11675925.

Wilson C, Swaroop P, Kumar S, Chopra A, Sharawat SK. Molecular leveraging of HOX-embedded non-coding RNAs in the progression of acute myeloid leukemia. Hum Cell. 2024 Nov 30;38(1):24. doi: 10.1007/s13577-024-01149-9. PMID: 39614990.

Guerra M, Marini A, Pagliarini V, Pitolli C, Coratti G, Bonvissuto D, Bravetti C, Pane M, Mercuri E, Sette C, Pera MC. High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes. Mol Neurobiol. 2025 May;62(5):5640-5649. doi: 10.1007/s12035-024-04605-7. Epub 2024 Nov 27. PMID: 39592557.

Liu X, Wang Y, Wang C, Wang X, Tang G, Xiong Z, Zhou W. Role of non-coding RNA in exosomes for the diagnosis and treatment of osteosarcoma. Front Oncol. 2024 Oct 24;14:1469833. doi: 10.3389/fonc.2024.1469833. PMID: 39512768; PMCID: PMC11540661.

Liu YB, Dai WH, Chang JJ, Wei K. CircRNA TUBA1C promotes proliferation and glucose metabolism, and blocks apoptosis of osteosarcoma cells through sponging miR-143-3p. Pol J Pathol. 2024;75(3):215-227. doi: 10.5114/pjp.2024.143231. PMID: 39451176.

Racca L, Liuzzi E, Comparato S, Giordano G, Pignochino Y. Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach. Int J Mol Sci. 2024 Aug 16;25(16):8934. doi: 10.3390/ijms25168934. PMID: 39201617; PMCID: PMC11354327.

Nejadi Orang F, Abdoli Shadbad M. CircRNA and lncRNA-associated competing endogenous RNA networks in medulloblastoma: a scoping review. Cancer Cell Int. 2024 Jul 15;24(1):248. doi: 10.1186/s12935-024-03427-w. PMID: 39010056; PMCID: PMC11251335.

Shu G, Zhao Z, Zhao T, Deng C, Zhu J, Han Y, Chen M, Jing J, Bai G, Li D, Li F, He J, Fu W, Liu G. N6-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor. J Exp Clin Cancer Res. 2024 Jul 11;43(1):191. doi: 10.1186/s13046-024-03113-9. Retraction in: J Exp Clin Cancer Res. 2025 Feb 18;44(1):59. doi: 10.1186/s13046-025-03326-6. PMID: 38987793; PMCID: PMC11238472.

Filomena A, Giovanni S, Ginevra S, Santiago N, Di Fasano Miriam S, Peppino M, Alessandra C, Antonia M, Giuliana B, Rosanna P, Marco S, Lorena B. Identification of a circular RNA isoform of WASHC2A as a prognostic factor for high-risk paediatric B-ALL patients. Biomed Pharmacother. 2024 Aug;177:116903. doi: 10.1016/j.biopha.2024.116903. Epub 2024 Jun 24. PMID: 38917755.

Sun H, Xie Y, Wu X, Hu W, Chen X, Wu K, Wang H, Zhao S, Shi Q, Wang X, Cui B, Wu W, Fan R, Rao J, Wang R, Wang Y, Zhong Y, Yu H, Zhou BS, Shen S, Liu Y. circRNAs as prognostic markers in pediatric acute myeloid leukemia. Cancer Lett. 2024 Jun 1;591:216880. doi: 10.1016/j.canlet.2024.216880. Epub 2024 Apr 15. PMID: 38621457.

Gutierrez-Camino A, Caron M, Richer C, Fuchs C, Illarregi U, Poncelet L, St-Onge P, Bataille AR, Tremblay-Dauphinais P, Lopez-Lopez E, Camos M, Ramirez-Orellana M, Astigarraga I, Lécuyer É, Bourque G, Martin-Guerrero I, Sinnett D. CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in *TCF3::PBX1* ALL. Int J Mol Sci. 2024 Jan 25;25(3):1477. doi: 10.3390/ijms25031477. PMID: 38338754; PMCID: PMC10855129.

Tretti Parenzan C, Molin AD, Longo G, Gaffo E, Buratin A, Cani A, Boldrin E, Serafin V, Guglielmelli P, Vannucchi AM, Cazzaniga G, Biondi A, Locatelli F, Meyer LH, Buldini B, Te Kronnie G, Bresolin S, Bortoluzzi S. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion. Blood Adv. 2024 Mar 12;8(5):1305-1319. doi: 10.1182/bloodadvances.2023011291. PMID: 38029383; PMCID: PMC10918493.

Liu L, Huang W. hsa\_circ\_0020378 regulating miR-339-3p/COL1A1 promotes osteosarcoma progression. Cancer Biol Ther. 2023 Dec 31;24(1):2274120. doi: 10.1080/15384047.2023.2274120. Epub 2023 Nov 18. PMID: 37978903; PMCID: PMC10761020.

Martinez de Estibariz I, Jakjimovska A, Illarregi U, Martin-Guerrero I, Gutiérrez-Camino A, Lopez-Lopez E, Bilbao-Aldaiturriaga N. The Role of the Dysregulation of Long Non-Coding and Circular RNA Expression in Medulloblastoma: A Systematic Review. Cancers (Basel). 2023 Sep 22;15(19):4686. doi: 10.3390/cancers15194686. PMID: 37835380; PMCID: PMC10571996.

Fu J, Si L, Zhou Y, Li D, Wang R. Distinct N7-methylguanosine profiles of circular RNAs in drug-resistant acute myeloid leukemia. Sci Rep. 2023 Sep 7;13(1):14704. doi: 10.1038/s41598-023-41974-w. PMID: 37679400; PMCID: PMC10485064.

Du J, Zhuo Y, Sun X, Nie M, Yang J, Luo X, Gu H. hsa\_circ\_0000285 sponging miR-582-3p promotes neuroblastoma progression by regulating the Wnt/β-catenin signaling pathway. Open Med (Wars). 2023 Jul 14;18(1):20230726. doi: 10.1515/med-2023-0726. PMID: 37465351; PMCID: PMC10350891.

Fuchs S, Danßmann C, Klironomos F, Winkler A, Fallmann J, Kruetzfeldt LM, Szymansky A, Naderi J, Bernhart SH, Grunewald L, Helmsauer K, Rodriguez-Fos E, Kirchner M, Mertins P, Astrahantseff K, Suenkel C, Toedling J, Meggetto F, Remke M, Stadler PF, Hundsdoerfer P, Deubzer HE, Künkele A, Lang P, Fuchs J, Henssen AG, Eggert A, Rajewsky N, Hertwig F, Schulte JH. Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN. Nat Commun. 2023 Jul 4;14(1):3936. doi: 10.1038/s41467-023-38747-4. PMID: 37402719; PMCID: PMC10319804.

Ye F, Fan C, Peng M, Liu S, Dong J, Yang L, Zhang H. Screening and validating circular RNAs that estimate disease risk and treatment response of pediatric acute myeloid leukemia: a microarray-based analyses and RT-qPCR validation. J Cancer Res Clin Oncol. 2023 Oct;149(13):11233-11245. doi: 10.1007/s00432-023-04879-9. Epub 2023 Jun 26. PMID: 37358666.

Deng W, Chao R, Zhu S. Emerging roles of circRNAs in leukemia and the clinical prospects: An update. Immun Inflamm Dis. 2023 Jan;11(1):e725. doi: 10.1002/iid3.725. PMID: 36705414; PMCID: PMC9801069.

Galardi A, Colletti M, Palma A, Di Giannatale A. An Update on Circular RNA in Pediatric Cancers. Biomedicines. 2022 Dec 23;11(1):36. doi: 10.3390/biomedicines11010036. PMID: 36672544; PMCID: PMC9856195.

Liu J, Qiu B. Identification of Circular RNA Circ\_0003256 as a Novel Player in Pediatric Acute Myeloid Leukemia. J Pediatr Hematol Oncol. 2023 Jan 1;45(1):29-37. doi: 10.1097/MPH.0000000000002372. Epub 2023 Jan 4. PMID: 36598961.

Chen HH, Zhang TN, Zhang FY, Zhang T. Non-coding RNAs in drug and radiation resistance of bone and soft-tissue sarcoma: a systematic review. Elife. 2022 Nov 3;11:e79655. doi: 10.7554/eLife.79655. PMID: 36326232; PMCID: PMC9691005.

Yang F, Liu Y, Xiao J, Li B, Chen Y, Hu A, Zeng J, Liu Z, Liu H. Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15. Cell Prolif. 2023 Jan;56(1):e13344. doi: 10.1111/cpr.13344. Epub 2022 Oct 1. PMID: 36181462; PMCID: PMC9816931.

Karami Fath M, Pourbagher Benam S, Salmani K, Naderi S, Fahham Z, Ghiabi S, Houshmand Kia SA, Naderi M, Darvish M, Barati G. Circular RNAs in neuroblastoma: Pathogenesis, potential biomarker, and therapeutic target. Pathol Res Pract. 2022 Oct;238:154094. doi: 10.1016/j.prp.2022.154094. Epub 2022 Aug 28. PMID: 36087416.

Li J, Han T, Li Z, Han H, Yin Y, Zhang B, Zhang H, Li L. A Novel circRNA hsa\_circRNA\_002178 as a Diagnostic Marker in Hepatocellular Carcinoma Enhances Cell Proliferation, Invasion, and Tumor Growth by Stabilizing SRSF1 Expression. J Oncol. 2022 Aug 27;2022:4184034. doi: 10.1155/2022/4184034. PMID: 36065311; PMCID: PMC9440807.

Azatyan A, Zaphiropoulos PG. Circular and Fusion RNAs in Medulloblastoma Development. Cancers (Basel). 2022 Jun 26;14(13):3134. doi: 10.3390/cancers14133134. PMID: 35804907; PMCID: PMC9264760.

Tian XM, Xiang B, Zhang ZX, Li YP, Shi QL, Li MJ, Li Q, Yu YH, Lu P, Liu F, Liu X, Lin T, He DW, Wei GH. The Regulatory Network and Role of the circRNA-miRNA-mRNA ceRNA Network in the Progression and the Immune Response of Wilms Tumor Based on RNA-Seq. Front Genet. 2022 Apr 26;13:849941. doi: 10.3389/fgene.2022.849941. PMID: 35559038; PMCID: PMC9086559.

Zhou Z, Wang Z, Gao J, Lin Z, Wang Y, Shan P, Li M, Zhou T, Li P. Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma. Mol Ther Oncolytics. 2022 Mar 16;25:98-120. doi: 10.1016/j.omto.2022.03.002. PMID: 35506150; PMCID: PMC9024380.

Liu XC, Wang FC, Wang JH, Zhao JY, Ye SY. The Circular RNA circSKA3 Facilitates the Malignant Biological Behaviors of Medulloblastoma via miR-520 h/CDK6 Pathway. Mol Biotechnol. 2022 Sep;64(9):1022-1033. doi: 10.1007/s12033-022-00466-4. Epub 2022 Mar 29. PMID: 35352283.

Liu Z, Spiegelman VS, Wang HG. Distinct noncoding RNAs and RNA binding proteins associated with high-risk pediatric and adult acute myeloid leukemias detected by regulatory network analysis. Cancer Rep (Hoboken). 2022 Oct;5(10):e1592. doi: 10.1002/cnr2.1592. Epub 2021 Dec 4. PMID: 34862757; PMCID: PMC9575484.

Babin L, Andraos E, Fuchs S, Pyronnet S, Brunet E, Meggetto F. From circRNAs to fusion circRNAs in hematological malignancies. JCI Insight. 2021 Nov 8;6(21):e151513. doi: 10.1172/jci.insight.151513. PMID: 34747369; PMCID: PMC8663548.

Liu X, Liu X, Cai M, Luo A, He Y, Liu S, Zhang X, Yang X, Xu L, Jiang H. CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia. Mol Cancer. 2021 Oct 26;20(1):139. doi: 10.1186/s12943-021-01395-7. PMID: 34702297; PMCID: PMC8549339.

Rickert D, Bartl J, Picard D, Bernardi F, Qin N, Lovino M, Puget S, Meyer FD, Mahoungou Koumba I, Beez T, Varlet P, Dufour C, Fischer U, Borkhardt A, Reifenberger G, Ayrault O, Remke M. Circular RNA profiling distinguishes medulloblastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma. Acta Neuropathol. 2021 Jun;141(6):975-978. doi: 10.1007/s00401-021-02306-2. Epub 2021 Apr 17. PMID: 33866410; PMCID: PMC8113310.

Zhao X, Guan J, Luo M. Circ-SKA3 upregulates ID3 expression by decoying miR-326 to accelerate the development of medulloblastoma. J Clin Neurosci. 2021 Apr;86:87-96. doi: 10.1016/j.jocn.2021.01.020. Epub 2021 Feb 2. PMID: 33775353.

Li Q, Luan Q, Zhu H, Zhao Y, Ji J, Wu F, Yan J. Circular RNA circ\_0005774 contributes to proliferation and suppresses apoptosis of acute myeloid leukemia cells via circ\_0005774/miR-192-5p/ULK1 ceRNA pathway. Biochem Biophys Res Commun. 2021 Apr 30;551:78-85. doi: 10.1016/j.bbrc.2021.02.058. Epub 2021 Mar 15. PMID: 33735626.

Chen Y, Lin L, Hu X, Li Q, Wu M. Silencing of circular RNA circPDE5A suppresses neuroblastoma progression by targeting the miR-362-5p/NOL4L axis. Int J Neurosci. 2023 Feb;133(2):141-151. doi: 10.1080/00207454.2021.1896505. Epub 2021 Mar 16. PMID: 33635749.

Liu J, Li X, Yue L, Lv H. Circ\_0105346 Knockdown Inhibits Osteosarcoma Development via Regulating miR-1182/WNT7B Axis. Cancer Manag Res. 2021 Jan 20;13:521-535. doi: 10.2147/CMAR.S281430. Retraction in: Cancer Manag Res. 2021 Jun 30;13:5161. doi: 10.2147/CMAR.S326513. PMID: 33505171; PMCID: PMC7829129.

Zhang B, Teng X, Yang W, Yang E, Li H, Jing S. CircRNA\_0084043 acts as a competitive endogenous RNA promotes osteosarcoma progression by sponging miR-153. Minerva Med. 2023 Feb;114(1):104-106. doi: 10.23736/S0026-4806.20.07229-8. Epub 2021 Jan 13. PMID: 33438380.

Torsin LI, Petrescu GED, Sabo AA, Chen B, Brehar FM, Dragomir MP, Calin GA. Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance. Int J Mol Sci. 2021 Jan 8;22(2):581. doi: 10.3390/ijms22020581. PMID: 33430133; PMCID: PMC7827606.

Ahmadov U, Bendikas MM, Ebbesen KK, Sehested AM, Kjems J, Broholm H, Kristensen LS. Distinct circular RNA expression profiles in pediatric ependymomas. Brain Pathol. 2021 Mar;31(2):387-392. doi: 10.1111/bpa.12922. Epub 2021 Jan 29. PMID: 33247464; PMCID: PMC8018153.

Latowska J, Grabowska A, Zarębska Ż, Kuczyński K, Kuczyńska B, Rolle K. Non-coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development-Their Diagnostic and Therapeutic Potential. Int J Mol Sci. 2020 Sep 23;21(19):7001. doi: 10.3390/ijms21197001. PMID: 32977537; PMCID: PMC7582339.

Lin Z, Long F, Zhao M, Zhang X, Yang M. The role of circular RNAs in hematological malignancies. Genomics. 2020 Nov;112(6):4000-4008. doi: 10.1016/j.ygeno.2020.06.051. Epub 2020 Jul 4. PMID: 32634468.

Skrzypek K, Majka M. Interplay among SNAIL Transcription Factor, MicroRNAs, Long Non-Coding RNAs, and Circular RNAs in the Regulation of Tumor Growth and Metastasis. Cancers (Basel). 2020 Jan 14;12(1):209. doi: 10.3390/cancers12010209. PMID: 31947678; PMCID: PMC7017348.

Ren C, Liu J, Zheng B, Yan P, Sun Y, Yue B. The circular RNA circ-ITCH acts as a tumour suppressor in osteosarcoma via regulating miR-22. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3359-3367. doi: 10.1080/21691401.2019.1649273. Retraction in: Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):165. doi: 10.1080/21691401.2021.2003035. PMID: 31387405.

Pisignano, G., Michael, D. C., Visal, T. H., Pirlog, R., Ladomery, M., & Calin, G. A. (2023). Going circular: history, present, and future of circRNAs in cancer. *Oncogene*, *42*(38), 2783-2800.

Zhang, F., Jiang, J., Qian, H., Yan, Y., & Xu, W. (2023). Exosomal circRNA: emerging insights into cancer progression and clinical application potential. *Journal of hematology & oncology*, *16*(1), 67.

Nielsen, A. F., Bindereif, A., Bozzoni, I., Hanan, M., Hansen, T. B., Irimia, M., ... & Kjems, J. (2022). Best practice standards for circular RNA research. *Nature methods*, *19*(10), 1208-1220.

Miao, Q., Ni, B., & Tang, J. (2021). Coding potential of circRNAs: new discoveries and challenges. *PeerJ*, *9*, e10718.

Mo, M. (2023). Non-coding RNAs in neurodegenerative diseases. *Frontiers in Neuroscience*, *17*, 1241737.

Yu, J., Yang, L., & Lu, H. (2021). The emerging role of circular RNAs in common solid malignant tumors in children. *Cancer Cell International*, *21*(1), 309.

Martinez de Estibariz, I., Jakjimovska, A., Illarregi, U., Martin-Guerrero, I., Gutierrez-Camino, A., Lopez-Lopez, E., & Bilbao-Aldaiturriaga, N. (2023). The Role of the Dysregulation of Long Non-Coding and Circular RNA Expression in Medulloblastoma: A Systematic Review. *Cancers*, *15*(19), 4686.

Zhang, J., Ju, Z., Zhang, H., Zhang, H., Zhou, R., Chan, G. C. F., ... & Wei, Y. (2025). CircRNA Profiles Analysis of Neuroblastoma for Identification of Drug Targets. *IEEE Transactions on Computational Biology and Bioinformatics*.

Galardi, A., Colletti, M., Palma, A., & Di Giannatale, A. (2022). An update on circular RNA in pediatric cancers. *Biomedicines*, *11*(1), 36.

Wang, H. S., Lao, J., Jiang, R. S., Wang, B., Ma, X. P., & Wang, J. Y. (2024). Summary of biological research on hepatoblastoma: a scoping review. *Frontiers in Pediatrics*, *12*, 1309693.

Asadi, M. R., Moslehian, M. S., Sabaie, H., Sharifi-Bonab, M., Hakimi, P., Hussen, B. M., ... & Rezazadeh, M. (2022). CircRNA-associated CeRNAs regulatory axes in retinoblastoma: a systematic scoping review. *Frontiers in Oncology*, *12*, 910470.

Wirth, B. (2021). Spinal muscular atrophy: in the challenge lies a solution. *Trends in neurosciences*, *44*(4), 306-322.